Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Modulation of Rb phosphorylation and antiproliferative response to palbociclib. The Preoperative-Palbociclib (POP) randomized Clinical Trial.

Arnedos M, Bayar MA, Cheaib B, Scott V, Bouakka I, Valent A, Adam J, Leroux-Kozal V, Marty V, Rapinat A, Mazouni C, Sarfati B, Bieche I, Balleyguier C, Gentien D, Delaloge S, Lacroix-Triki M, Michiels S, Andre F.

Ann Oncol. 2018 Jun 11. doi: 10.1093/annonc/mdy202. [Epub ahead of print]

PMID:
29893769
2.

The iron chelator deferasirox synergizes with chemotherapy to treat triple negative breast cancers.

Tury S, Assayag F, Bonin F, Chateau-Joubert S, Servely JL, Vacher S, Becette V, Caly M, Rapinat A, Gentien D, de la Grange P, Schnitzler A, Lallemand F, Marangoni E, Bièche I, Callens C.

J Pathol. 2018 Jun 7. doi: 10.1002/path.5104. [Epub ahead of print]

PMID:
29876931
3.

LRP5 regulates the expression of STK40, a new potential target in triple-negative breast cancers.

Maubant S, Tahtouh T, Brisson A, Maire V, Némati F, Tesson B, Ye M, Rigaill G, Noizet M, Dumont A, Gentien D, Marty-Prouvost B, de Koning L, Mahmood SF, Decaudin D, Cruzalegui F, Tucker GC, Roman-Roman S, Dubois T.

Oncotarget. 2018 Apr 27;9(32):22586-22604. doi: 10.18632/oncotarget.25187. eCollection 2018 Apr 27.

4.

A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.

Huet S, Tesson B, Jais JP, Feldman AL, Magnano L, Thomas E, Traverse-Glehen A, Albaud B, Carrère M, Xerri L, Ansell SM, Baseggio L, Reyes C, Tarte K, Boyault S, Haioun C, Link BK, Feugier P, Lopez-Guillermo A, Tilly H, Brice P, Hayette S, Jardin F, Offner F, Sujobert P, Gentien D, Viari A, Campo E, Cerhan JR, Salles G.

Lancet Oncol. 2018 Apr;19(4):549-561. doi: 10.1016/S1470-2045(18)30102-5. Epub 2018 Feb 20. Erratum in: Lancet Oncol. 2018 Jun;19(6):e283.

PMID:
29475724
5.

Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers.

Marangoni E, Laurent C, Coussy F, El-Botty R, Château-Joubert S, Servely JL, de Plater L, Assayag F, Dahmani A, Montaudon E, Nemati F, Fleury J, Vacher S, Gentien D, Rapinat A, Foidart P, Sounni NE, Noel A, Vincent-Salomon A, Lae M, Decaudin D, Roman-Roman S, Bièche I, Piccart M, Reyal F.

Clin Cancer Res. 2018 Jun 1;24(11):2605-2615. doi: 10.1158/1078-0432.CCR-17-3490. Epub 2018 Feb 20.

PMID:
29463559
6.

Distinctive roles of age, sex, and genetics in shaping transcriptional variation of human immune responses to microbial challenges.

Piasecka B, Duffy D, Urrutia A, Quach H, Patin E, Posseme C, Bergstedt J, Charbit B, Rouilly V, MacPherson CR, Hasan M, Albaud B, Gentien D, Fellay J, Albert ML, Quintana-Murci L; Milieu Intérieur Consortium.

Proc Natl Acad Sci U S A. 2018 Jan 16;115(3):E488-E497. doi: 10.1073/pnas.1714765115. Epub 2017 Dec 27.

7.

Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancers.

Hequet D, Callens C, Gentien D, Albaud B, Mouret-Reynier MA, Dubot C, Cottu P, Huchon C, Zilberman S, Berseneff H, Foa C, Salmon R, Roulot A, Lerebours F, Salomon A, Ghali N, Morel P, Li Q, Cayre A, Guinebretière JM, Hornberger J, Penault-Llorca F, Rouzier R.

PLoS One. 2017 Oct 18;12(10):e0185753. doi: 10.1371/journal.pone.0185753. eCollection 2017.

8.

[Neurotrophic factors for motor neurons: an à la carte menu].

Alory A, Jacquier A, Gentien D, de la Grange P, Haase G.

Med Sci (Paris). 2017 Oct;33(10):835-839. doi: 10.1051/medsci/20173310008. Epub 2017 Oct 10. French. No abstract available.

PMID:
28994373
9.

Reliable subtype classification of diffuse large B-cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay.

Jais JP, Molina TJ, Ruminy P, Gentien D, Reyes C, Scott DW, Rimsza LM, Wright G, Gascoyne RD, Staudt LM, Haioun C, Tilly H, Gaulard P, Salles GA, Jardin F, Leroy K.

Haematologica. 2017 Oct;102(10):e404-e406. doi: 10.3324/haematol.2017.166827. Epub 2017 Jul 4. No abstract available.

10.

Embryonic signature distinguishes pediatric and adult rhabdoid tumors from other SMARCB1-deficient cancers.

Richer W, Masliah-Planchon J, Clement N, Jimenez I, Maillot L, Gentien D, Albaud B, Chemlali W, Galant C, Larousserie F, Boudou-Rouquette P, Leruste A, Chauvin C, Han ZY, Coindre JM, Varlet P, Freneaux P, Ranchère-Vince D, Delattre O, Bourdeaut F.

Oncotarget. 2017 May 23;8(21):34245-34257. doi: 10.18632/oncotarget.15939.

11.

Novel combinatorial screening identifies neurotrophic factors for selective classes of motor neurons.

Schaller S, Buttigieg D, Alory A, Jacquier A, Barad M, Merchant M, Gentien D, de la Grange P, Haase G.

Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):E2486-E2493. doi: 10.1073/pnas.1615372114. Epub 2017 Mar 7.

12.

Nanobodies against surface biomarkers enable the analysis of tumor genetic heterogeneity in uveal melanoma patient-derived xenografts.

Crépin R, Gentien D, Duché A, Rapinat A, Reyes C, Némati F, Massonnet G, Decaudin D, Djender S, Moutel S, Desrumeaux K, Cassoux N, Piperno-Neumann S, Amigorena S, Perez F, Roman-Roman S, de Marco A.

Pigment Cell Melanoma Res. 2017 May;30(3):317-327. doi: 10.1111/pcmr.12577. Epub 2017 Apr 19.

PMID:
28140525
13.

Evisceration and ocular tumors: What are the consequences?

Lemaître S, Lecler A, Lévy-Gabriel C, Reyes C, Desjardins L, Gentien D, Zmuda M, Jacomet PV, Lumbroso-Le Rouic L, Dendale R, Vincent-Salomon A, Pierron G, Galatoire O, Cassoux N.

J Fr Ophtalmol. 2017 Feb;40(2):93-101. doi: 10.1016/j.jfo.2016.10.007. Epub 2017 Jan 23.

PMID:
28126270
14.

Denaturing fixatives are compatible with the NanoString nCounter® platform and the Prosigna® assay.

Rouzier R, Roulot A, Jeiranian AH, Ram N, Guinebretiere JM, Salomon AV, Gentien D.

N Biotechnol. 2017 May 25;36:37-41. doi: 10.1016/j.nbt.2017.01.001. Epub 2017 Jan 6.

PMID:
28069519
15.

Standardized Whole-Blood Transcriptional Profiling Enables the Deconvolution of Complex Induced Immune Responses.

Urrutia A, Duffy D, Rouilly V, Posseme C, Djebali R, Illanes G, Libri V, Albaud B, Gentien D, Piasecka B, Hasan M, Fontes M, Quintana-Murci L, Albert ML; Milieu Intérieur Consortium.

Cell Rep. 2016 Sep 6;16(10):2777-2791. doi: 10.1016/j.celrep.2016.08.011. Epub 2016 Aug 25.

16.

Genomic Copy Number Profiling Using Circulating Free Tumor DNA Highlights Heterogeneity in Neuroblastoma.

Chicard M, Boyault S, Colmet Daage L, Richer W, Gentien D, Pierron G, Lapouble E, Bellini A, Clement N, Iacono I, Bréjon S, Carrere M, Reyes C, Hocking T, Bernard V, Peuchmaur M, Corradini N, Faure-Conter C, Coze C, Plantaz D, Defachelles AS, Thebaud E, Gambart M, Millot F, Valteau-Couanet D, Michon J, Puisieux A, Delattre O, Combaret V, Schleiermacher G.

Clin Cancer Res. 2016 Nov 15;22(22):5564-5573. doi: 10.1158/1078-0432.CCR-16-0500. Epub 2016 Jul 20.

17.

Characterization of Breast Cancer Preclinical Models Reveals a Specific Pattern of Macrophage Polarization.

Vallerand D, Massonnet G, Kébir F, Gentien D, Maciorowski Z, De la Grange P, Sigal-Zafrani B, Richardson M, Humbert S, Thuleau A, Assayag F, de Plater L, Nicolas A, Scholl S, Marangoni E, Weigand S, Roman-Roman S, Savina A, Decaudin D.

PLoS One. 2016 Jul 7;11(7):e0157670. doi: 10.1371/journal.pone.0157670. eCollection 2016.

18.

Chromatin Regulators as a Guide for Cancer Treatment Choice.

Gurard-Levin ZA, Wilson LO, Pancaldi V, Postel-Vinay S, Sousa FG, Reyes C, Marangoni E, Gentien D, Valencia A, Pommier Y, Cottu P, Almouzni G.

Mol Cancer Ther. 2016 Jul;15(7):1768-77. doi: 10.1158/1535-7163.MCT-15-1008. Epub 2016 May 16.

19.

The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma.

Amirouchene-Angelozzi N, Frisch-Dit-Leitz E, Carita G, Dahmani A, Raymondie C, Liot G, Gentien D, Némati F, Decaudin D, Roman-Roman S, Schoumacher M.

Oncotarget. 2016 Apr 26;7(17):23633-46. doi: 10.18632/oncotarget.8054.

20.

Estrogen-Receptor, Progesterone-Receptor and HER2 Status Determination in Invasive Breast Cancer. Concordance between Immuno-Histochemistry and MapQuant™ Microarray Based Assay.

Mouttet D, Laé M, Caly M, Gentien D, Carpentier S, Peyro-Saint-Paul H, Vincent-Salomon A, Rouzier R, Sigal-Zafrani B, Sastre-Garau X, Reyal F.

PLoS One. 2016 Feb 1;11(2):e0146474. doi: 10.1371/journal.pone.0146474. eCollection 2016.

21.

Massively parallel DNA sequencing from routinely processed cytological smears.

Piqueret-Stephan L, Marcaillou C, Reyes C, Honoré A, Letexier M, Gentien D, Droin N, Lacroix L, Scoazec JY, Vielh P.

Cancer Cytopathol. 2016 Apr;124(4):241-53. doi: 10.1002/cncy.21639. Epub 2015 Oct 27.

22.

Balanced Translocations Disrupting SMARCB1 Are Hallmark Recurrent Genetic Alterations in Renal Medullary Carcinomas.

Calderaro J, Masliah-Planchon J, Richer W, Maillot L, Maille P, Mansuy L, Bastien C, de la Taille A, Boussion H, Charpy C, Jourdain A, Bléchet C, Pierron G, Gentien D, Choudat L, Tournigand C, Delattre O, Allory Y, Bourdeaut F.

Eur Urol. 2016 Jun;69(6):1055-61. doi: 10.1016/j.eururo.2015.09.027. Epub 2015 Oct 1.

PMID:
26433572
23.

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.

Le Tourneau C, Delord JP, Gonçalves A, Gavoille C, Dubot C, Isambert N, Campone M, Trédan O, Massiani MA, Mauborgne C, Armanet S, Servant N, Bièche I, Bernard V, Gentien D, Jezequel P, Attignon V, Boyault S, Vincent-Salomon A, Servois V, Sablin MP, Kamal M, Paoletti X; SHIVA investigators.

Lancet Oncol. 2015 Oct;16(13):1324-34. doi: 10.1016/S1470-2045(15)00188-6. Epub 2015 Sep 3.

PMID:
26342236
24.

TIPIN depletion leads to apoptosis in breast cancer cells.

Baldeyron C, Brisson A, Tesson B, Némati F, Koundrioukoff S, Saliba E, De Koning L, Martel E, Ye M, Rigaill G, Meseure D, Nicolas A, Gentien D, Decaudin D, Debatisse M, Depil S, Cruzalegui F, Pierré A, Roman-Roman S, Tucker GC, Dubois T.

Mol Oncol. 2015 Oct;9(8):1580-98. doi: 10.1016/j.molonc.2015.04.010. Epub 2015 May 9.

25.

Histo-genomic stratification reveals the frequent amplification/overexpression of CCNE1 and BRD4 genes in non-BRCAness high grade ovarian carcinoma.

Goundiam O, Gestraud P, Popova T, De la Motte Rouge T, Fourchotte V, Gentien D, Hupé P, Becette V, Houdayer C, Roman-Roman S, Stern MH, Sastre-Garau X.

Int J Cancer. 2015 Oct 15;137(8):1890-900. doi: 10.1002/ijc.29568. Epub 2015 Apr 29.

26.

Transcriptome analysis of Wnt3a-treated triple-negative breast cancer cells.

Maubant S, Tesson B, Maire V, Ye M, Rigaill G, Gentien D, Cruzalegui F, Tucker GC, Roman-Roman S, Dubois T.

PLoS One. 2015 Apr 7;10(4):e0122333. doi: 10.1371/journal.pone.0122333. eCollection 2015.

27.

The inactive X chromosome is epigenetically unstable and transcriptionally labile in breast cancer.

Chaligné R, Popova T, Mendoza-Parra MA, Saleem MA, Gentien D, Ban K, Piolot T, Leroy O, Mariani O, Gronemeyer H, Vincent-Salomon A, Stern MH, Heard E.

Genome Res. 2015 Apr;25(4):488-503. doi: 10.1101/gr.185926.114. Epub 2015 Feb 4.

28.

Multi-factor data normalization enables the detection of copy number aberrations in amplicon sequencing data.

Boeva V, Popova T, Lienard M, Toffoli S, Kamal M, Le Tourneau C, Gentien D, Servant N, Gestraud P, Rio Frio T, Hupé P, Barillot E, Laes JF.

Bioinformatics. 2014 Dec 15;30(24):3443-50. doi: 10.1093/bioinformatics/btu436. Epub 2014 Jul 12.

29.

Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target.

Amirouchene-Angelozzi N, Nemati F, Gentien D, Nicolas A, Dumont A, Carita G, Camonis J, Desjardins L, Cassoux N, Piperno-Neumann S, Mariani P, Sastre X, Decaudin D, Roman-Roman S.

Mol Oncol. 2014 Dec;8(8):1508-20. doi: 10.1016/j.molonc.2014.06.004. Epub 2014 Jun 13.

30.

Acquired resistance to endocrine treatments is associated with tumor-specific molecular changes in patient-derived luminal breast cancer xenografts.

Cottu P, Bièche I, Assayag F, El Botty R, Chateau-Joubert S, Thuleau A, Bagarre T, Albaud B, Rapinat A, Gentien D, de la Grange P, Sibut V, Vacher S, Hatem R, Servely JL, Fontaine JJ, Decaudin D, Pierga JY, Roman-Roman S, Marangoni E.

Clin Cancer Res. 2014 Aug 15;20(16):4314-25. doi: 10.1158/1078-0432.CCR-13-3230. Epub 2014 Jun 19.

31.

Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial.

Le Tourneau C, Paoletti X, Servant N, Bièche I, Gentien D, Rio Frio T, Vincent-Salomon A, Servois V, Romejon J, Mariani O, Bernard V, Huppe P, Pierron G, Mulot F, Callens C, Wong J, Mauborgne C, Rouleau E, Reyes C, Henry E, Leroy Q, Gestraud P, La Rosa P, Escalup L, Mitry E, Trédan O, Delord JP, Campone M, Goncalves A, Isambert N, Gavoille C, Kamal M.

Br J Cancer. 2014 Jul 8;111(1):17-24. doi: 10.1038/bjc.2014.211. Epub 2014 Apr 24.

32.

Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER).

André F, Bachelot T, Commo F, Campone M, Arnedos M, Dieras V, Lacroix-Triki M, Lacroix L, Cohen P, Gentien D, Adélaide J, Dalenc F, Goncalves A, Levy C, Ferrero JM, Bonneterre J, Lefeuvre C, Jimenez M, Filleron T, Bonnefoi H.

Lancet Oncol. 2014 Mar;15(3):267-74. doi: 10.1016/S1470-2045(13)70611-9. Epub 2014 Feb 7.

PMID:
24508104
33.

A common alternative splicing signature is associated with SF3B1 mutations in malignancies from different cell lineages.

Gentien D, Kosmider O, Nguyen-Khac F, Albaud B, Rapinat A, Dumont AG, Damm F, Popova T, Marais R, Fontenay M, Roman-Roman S, Bernard OA, Stern MH.

Leukemia. 2014 Jun;28(6):1355-7. doi: 10.1038/leu.2014.28. Epub 2014 Jan 17. No abstract available.

PMID:
24434863
34.

Genomic instability: a stronger prognostic marker than proliferation for early stage luminal breast carcinomas.

Vincent-Salomon A, Benhamo V, Gravier E, Rigaill G, Gruel N, Robin S, de Rycke Y, Mariani O, Pierron G, Gentien D, Reyal F, Cottu P, Fourquet A, Rouzier R, Sastre-Garau X, Delattre O.

PLoS One. 2013 Oct 15;8(10):e76496. doi: 10.1371/journal.pone.0076496. eCollection 2013.

35.

Challenging single- and multi-probesets gene expression signatures of pathological complete response to neoadjuvant chemotherapy in breast cancer: experience of the REMAGUS 02 phase II trial.

Valet F, de Cremoux P, Spyratos F, Servant N, Dujaric ME, Gentien D, Lehmann-Che J, Scott V, Sigal-Zafrani B, Mathieu MC, Bertheau P, Guinebretière JM, Pierga JY, Delaloge S, Giacchetti S, Brain E, Tembo O, Marty M, Asselain B.

Breast. 2013 Dec;22(6):1052-9. doi: 10.1016/j.breast.2013.08.015. Epub 2013 Oct 2.

PMID:
24095610
36.

Genomic amplification is not a frequent event in uveal melanomas.

Rodrigues MJ, Gentien D, Stern MH, Desjardins L, Couturier J.

Am J Pathol. 2013 Aug;183(2):638. doi: 10.1016/j.ajpath.2013.04.032.

PMID:
23885717
37.

SF3B1 mutations are associated with alternative splicing in uveal melanoma.

Furney SJ, Pedersen M, Gentien D, Dumont AG, Rapinat A, Desjardins L, Turajlic S, Piperno-Neumann S, de la Grange P, Roman-Roman S, Stern MH, Marais R.

Cancer Discov. 2013 Oct;3(10):1122-1129. doi: 10.1158/2159-8290.CD-13-0330. Epub 2013 Jul 16.

38.

TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer.

Maire V, Baldeyron C, Richardson M, Tesson B, Vincent-Salomon A, Gravier E, Marty-Prouvost B, De Koning L, Rigaill G, Dumont A, Gentien D, Barillot E, Roman-Roman S, Depil S, Cruzalegui F, Pierré A, Tucker GC, Dubois T.

PLoS One. 2013 May 20;8(5):e63712. doi: 10.1371/journal.pone.0063712. Print 2013.

39.

Patient-derived xenografts recapitulate molecular features of human uveal melanomas.

Laurent C, Gentien D, Piperno-Neumann S, Némati F, Nicolas A, Tesson B, Desjardins L, Mariani P, Rapinat A, Sastre-Garau X, Couturier J, Hupé P, de Koning L, Dubois T, Roman-Roman S, Stern MH, Barillot E, Harbour JW, Saule S, Decaudin D.

Mol Oncol. 2013 Jun;7(3):625-36. doi: 10.1016/j.molonc.2013.02.004. Epub 2013 Feb 26.

40.

Telomere crisis in kidney epithelial cells promotes the acquisition of a microRNA signature retrieved in aggressive renal cell carcinomas.

Castro-Vega LJ, Jouravleva K, Liu WY, Martinez C, Gestraud P, Hupé P, Servant N, Albaud B, Gentien D, Gad S, Richard S, Bacchetti S, Londoño-Vallejo A.

Carcinogenesis. 2013 May;34(5):1173-80. doi: 10.1093/carcin/bgt029. Epub 2013 Jan 27.

PMID:
23358853
41.

The Huntington disease protein accelerates breast tumour development and metastasis through ErbB2/HER2 signalling.

Moreira Sousa C, McGuire JR, Thion MS, Gentien D, de la Grange P, Tezenas du Montcel S, Vincent-Salomon A, Durr A, Humbert S.

EMBO Mol Med. 2013 Feb;5(2):309-25. doi: 10.1002/emmm.201201546. Epub 2013 Jan 9.

42.

Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial.

Le Tourneau C, Kamal M, Trédan O, Delord JP, Campone M, Goncalves A, Isambert N, Conroy T, Gentien D, Vincent-Salomon A, Pouliquen AL, Servant N, Stern MH, Le Corroller AG, Armanet S, Rio Frio T, Paoletti X.

Target Oncol. 2012 Dec;7(4):253-65. doi: 10.1007/s11523-012-0237-6. Epub 2012 Nov 17. Review.

PMID:
23161020
43.

Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer.

Maire V, Némati F, Richardson M, Vincent-Salomon A, Tesson B, Rigaill G, Gravier E, Marty-Prouvost B, De Koning L, Lang G, Gentien D, Dumont A, Barillot E, Marangoni E, Decaudin D, Roman-Roman S, Pierré A, Cruzalegui F, Depil S, Tucker GC, Dubois T.

Cancer Res. 2013 Jan 15;73(2):813-23. doi: 10.1158/0008-5472.CAN-12-2633. Epub 2012 Nov 9.

44.

Large-scale chromatin immunoprecipitation with promoter sequence microarray analysis of the interaction of the NSs protein of Rift Valley fever virus with regulatory DNA regions of the host genome.

Benferhat R, Josse T, Albaud B, Gentien D, Mansuroglu Z, Marcato V, Souès S, Le Bonniec B, Bouloy M, Bonnefoy E.

J Virol. 2012 Oct;86(20):11333-44. Epub 2012 Aug 15.

45.

Pyrophosphorolysis-activated polymerization detects circulating tumor DNA in metastatic uveal melanoma.

Madic J, Piperno-Neumann S, Servois V, Rampanou A, Milder M, Trouiller B, Gentien D, Saada S, Assayag F, Thuleau A, Nemati F, Decaudin D, Bidard FC, Desjardins L, Mariani P, Lantz O, Stern MH.

Clin Cancer Res. 2012 Jul 15;18(14):3934-41. doi: 10.1158/1078-0432.CCR-12-0309. Epub 2012 May 29.

46.

Respective prognostic value of genomic grade and histological proliferation markers in early stage (pN0) breast carcinoma.

Reyal F, Bollet MA, Caly M, Gentien D, Carpentier S, Peyro-Saint-Paul H, Pierga JY, Cottu P, Dieras V, Sigal-Zafrani B, Vincent-Salomon A, Sastre-Garau X.

PLoS One. 2012;7(4):e35184. doi: 10.1371/journal.pone.0035184. Epub 2012 Apr 18. Erratum in: PLoS One. 2012;7(7). doi: 10.1371/annotation/46dc7048-61b1-45bd-b4cd-a3b80a2f3f5a.

47.

Molecular profiling of patient-derived breast cancer xenografts.

Reyal F, Guyader C, Decraene C, Lucchesi C, Auger N, Assayag F, De Plater L, Gentien D, Poupon MF, Cottu P, De Cremoux P, Gestraud P, Vincent-Salomon A, Fontaine JJ, Roman-Roman S, Delattre O, Decaudin D, Marangoni E.

Breast Cancer Res. 2012 Jan 16;14(1):R11.

48.

Modeling of response to endocrine therapy in a panel of human luminal breast cancer xenografts.

Cottu P, Marangoni E, Assayag F, de Cremoux P, Vincent-Salomon A, Guyader Ch, de Plater L, Elbaz C, Karboul N, Fontaine JJ, Chateau-Joubert S, Boudou-Rouquette P, Alran S, Dangles-Marie V, Gentien D, Poupon MF, Decaudin D.

Breast Cancer Res Treat. 2012 Jun;133(2):595-606. doi: 10.1007/s10549-011-1815-5. Epub 2011 Oct 16.

PMID:
22002565
49.

Sperm transcriptome profiling in oligozoospermia.

Montjean D, De La Grange P, Gentien D, Rapinat A, Belloc S, Cohen-Bacrie P, Menezo Y, Benkhalifa M.

J Assist Reprod Genet. 2012 Jan;29(1):3-10. doi: 10.1007/s10815-011-9644-3. Epub 2011 Oct 12.

50.

Importance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patients.

de Cremoux P, Valet F, Gentien D, Lehmann-Che J, Scott V, Tran-Perennou C, Barbaroux C, Servant N, Vacher S, Sigal-Zafrani B, Mathieu MC, Bertheau P, Guinebretière JM, Asselain B, Marty M, Spyratos F.

BMC Cancer. 2011 Jun 1;11:215. doi: 10.1186/1471-2407-11-215.

Supplemental Content

Loading ...
Support Center